BMYMirati Therapeutics Inc.Running, no new patients
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Advanced NSCLC · Metastatic Lung Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 90 (planned)
- Started
- Nov 22, 2022
- Main results expected
- Sep 30, 2026
- Fully finished
- Dec 1, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) for Cohort A and E
Measured over: 30 months
Progression-free Survival (PFS) at six months for Cohort C
Measured over: 30 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05609578 · record last updated 2026-06-23 · checked 2026-11-09 15:47 UTC